治疗放射学阴性中轴型脊柱关节炎新药:培塞利珠单抗

A new drug in treatment of non-radiographic axial spondyloarthritis:certolizumab pegol

培塞利珠单抗是一种肿瘤坏死因子抑制剂,由比利时优时比制药公司研制,于2008年经美国食品和药物管理局批准上市后,用于治疗成人克罗恩病、中重度类风湿关节炎、银屑病关节炎、强直性脊柱炎和中重度斑块状银屑病,2019年3月28日被批准用于治疗放射学阴性中轴型脊柱关节炎。推荐用法为起始0、2和4周皮下注射给药1次,每次400 mg,后每2周给药1次(每次200 mg),或每4周1次(每次400 mg)。培塞利珠单抗常见不良反应为鼻咽炎、上呼吸道感染、头痛、血肌酸激酶升高,长期应用有增加严重感染和恶性肿瘤的风险。

Certolizumab pegol is a tumor necrosis factor inhibitor.It was developed by UCB S.A.,Belgium.From 2008,certolizumab pegol has been approved by the U.S.Food and Drug Adiministration for the treatment of adult Crohn’s disease,moderate to severe rheumatoid arthritis,psoriatic arthritis,axial spondyloarthritis and moderate to severe plaque psoriasis.It was approved for the treatment of non-radiographic axial spondyloarthritis on March 28,2019.The recommended dosage of certolizumab pegol is 400 mg subcutaneously at week 0,2 and 4,followed by 200 mg every two weeks or 400 mg every four weeks.The common adverse reactions are nasopharyngitis,upper respiratory tract infection,headache,and increased creatine phosphokinase.Long-term application of certolizumab pegol increases the risk of severe infection and malignancy.